Besivance
(Besifloxacin)ApprovedSmall molecule
Besivance is one of 61 small molecule programs targeting Keratitis. It is currently in Approved.
2
Indications
9
Total Trials
0
Active Trials
60
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
4
Patents
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
63 competitors in Cataract
#DrugCompanyPhaseTrials
1Eylea
RegeneronApproved
Avelox
BayerApproved
Decadron
AAspen Global Incorporated
Approved
Bromday
BBausch Health Americas, Inc.
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Lovenox
SanofiApproved
Toradol
RocheApproved
Cipro
BayerApproved
Voltaren
NovartisApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Bacterial Conjunctivitis3 trials
Concentration2 trials
Cataract2 trials
Absorption1 trial
Keratitis1 trial
Besifloxacin in Bacterial Keratitis
Completed·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·N/A·NCT02497365·32 enrolled
Regulatory
FDA Approval Timeline[4]
May 28, 2009
BESIVANCE
NDA NDA022308
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Besifloxacin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
- [6]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- BBausch Health Americas, Inc.